Abstract:Objective: Accurate diagnostic assessment of human epidermal growth factor receptor-2 (HER-2) is essential and a prerequisite for appropriate application of the humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) to the treatment of patients with breast cancer. Immunohistochemistry (IHC) is the most widely applicable diagnostic modality in studying HER-2 status. Fluorescence in situ hybridization (FISH) is also recognized as a modality in cases with an equivocal IHC status (score, 2+). Some authors claimed that FISH alone is sufficient. The aim of this study was to correlate the test results of IHC and FISH for HER-2 gene amplification in breast cancer patients. FISH for topoisomerase IIalpha (TOP2A) was also studied to see if deletion or amplification of TOP2A has any supplementary role to HER-2, FISH and IHC. Materials and methods: Assessment of HER-2 gene amplification and TOP2A gene amplification/deletion was made by FISH analysis using the LSI TOP2A/HER-2/CEP 17 multicolor probe or the LSI HER-2/CEP dual color probe (Vysis, Downers Grove, IL, USA) in formalin-fixed and paraffin-embedded tissue sections of 54 breast cancer patients who were grouped into stages 1+, 2+ or 3+ based on IHC (HercepTest; DakoCytomation, Carpinteria, CA, USA) observations. Results: None of IHC 1+ breast tumors was HER-2 FISH positive, but three of 18 (17%) IHC 3+ tumors were HER-2 FISH negative. Overall, 53% of the IHC 2+ and 83% of the IHC 3+ cases were HER-2 FISH positive. Only one case with IHC 3+ tumor that was HER-2 FISH positive was found to have TOP2A amplification (>2.0) and no IHC 2+ cases were found to have TOP2A amplification. There were no cases with TOP2A deletion (<0.8) in our whole series. There were also no cases of HER-2 FISH negative tumors, but IHC scored as 2+ or 3+ (0 of 10), to be found with TOP2A amplification. The discordance rates by IHC were high (46.7% in IHC 2+, 16.7% in IHC 3+, 30.3% overall in IHC 2+ or 3+). On the contrary, the discordance rates were zero if by FISH. Conclusion: The current algorithm to use HER-2 FISH as a supplementary role to IHC HercepTest 2+ may need some modifications according to the local setting. TOP2A FISH adds little value to HER-2 FISH and IHC staining in our study.

Comparison of Immunohistochemistry and Fluorescence in Situ Hybridization in Detecting C-Erbb-2 Expression in Breast Cancer

A Comparative Study on HER-2 Expression by Immunohistochemistry and Fluorescence in Situ Hybridization in Breast Cancer Tissue

Comparision of HER2/neu Oncogene Detected by Chromogenic In-Situ Hybridization and Immunohistochemistry in Breast Cancer

The Expression and Clinical Significance of PCNA and C-erbB-2 in Breast Cancer Tissue

Consistency of HER-2 Expression Detected by Both Immunohistochemistry and Fluorescence in Situ Hybridization in Gastric Cancer

Expression of C-erbB-2 Protein in Different Sliding Techniques of Breast Cancer

Investigation of HER-2 status evaluated by both IHC and FISH approaches in 278 cases of invasive breast carcinoma

HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases.

Detection of HER-2 Mrna and Protein Expression in Breast Cancer Tissues by Using Chromogenic in Situ Hybridization and Immunohistochemistry Methods

Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization

Evaluation of HER2 Oncogene Amplification and Overexpression in Breast Cancer and Their Clinical Significance

The detection of HER-2 protein and gene in the human breast cancer and its clinical significance

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients

Differential Expression and Its Clinical Significance of Amplification in Her-2 Gene and Protein with Breast Cancer

[Analysis of HER2 Gene Amplification and Its Protein Expression in 165 Cases of Breast Carcinoma: Comparison of Chromogenic In-Situ Hybridization and Immunohistochemistry].

[Assessment of HER2 Gene Amplification in Breast Cancer: a Comparison of Dual-Color In-Situ Hybridization and Fluorescence In-Situ Hybridization].

A comparative study on assessment of HER-2 of invasive breast cancers by using FDA and ASCO/CAP scoring systems

[Reliability of Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer Evaluated by Immunohistochemistry].

In Situ Hybridization Status of 568 Cases of HER2 Equivocal Breast Cancer

Relationship Between Images of Color Doppler Ultrasonography and C-Erbb-2 Expression in Patients with Breast Cancer

A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer